Acute Myeloid Leukemia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

Acute Myeloid Leukemia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Acute Myeloid Leukemia therapeutics.

Synopsis

In 2022, there will be more than 156,000 diagnosed prevalent cases of acute myeloid leukemia across 16 pharmaceutical markets.

There are 10 leading marketed drugs for the treatment of acute myeloid leukemia, Bristol Myers Squibb is a key player in the disease space.

R&D activity in acute myeloid leukemia is active globally, with 18 products in late-stage development.

Non-commercial sponsors dominate clinical trial development in acute myeloid leukemia, with the US emerging as the key countries for conducting trials in acute myeloid leukemia.

Deals involving strategic alliances of acute myeloid leukemia assets are the most common type of deals globally.

One commercial launch is expected for acute myeloid leukemia in the next 18 months in the US.

Scope

GlobalData’s Acute Myeloid Leukemia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

Disease Landscape

Disease Overview

Epidemiology Overview

Treatment Overview

Marketed Products Assessment

Breakdown by Mechanism of Action, Molecule Type and Route of Administration

Product Profiles with Sales Forecast

Pipeline Assessment

Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

Late-to-mid-stage Pipeline Drugs

Phase Transition Success Rate and Likelihood of Approval

Clinical Trials Assessment

Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

Enrolment Analytics, Site Analytics, Feasibility Analysis

Deals Landscape

Mergers, Acquisitions, and Strategic Alliances by Region

Overview of Recent Deals

Commercial Assessment

Key Market Players

Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Acute Myeloid Leukemia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Acute Myeloid Leukemia market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.